1-20 of 69 results for subject:Patients
Librarians' tools
- Search time
- 0.286 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:Patients
- We searched for
- subject_t:Patients OR subject_t:"Sick people" OR subject_ses:92375
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government what assessment they have made of the impact of Healthwatch on patient involvement in the NHS.
To ask His Majesty's Government what assessment they have made of the impact of Healthwatch on patient involvement in the NHS.
Healthwatch has played an important role in supporting patient involvement in the National Health Service, and in our 10-Year Health Plan we recognise the valuable work they have done to gather patient feedback and influence the debate around local service delivery.
Healthwatch was one of six organisations covered by Dr Penny Dash’s review of patient safety across the health and care landscape. The review found that there are too many organisations doing this type of work, which can create confusion for patients and risks limiting impact given their distance from service providers and commissioners.
In response, we have committed in our 10-Year Health Plan to bring Healthwatch England’s strategic functions ‘in house’ within a reformed Department, giving patients a stronger national voice through the creation of a new National Director of Patient Experience. At the same time, the statutory functions of Local Healthwatch will be brought together with the involvement and engagement responsibilities of integrated care boards, ensuring that patient insight is more directly connected to local decision-making and service improvement.
To ask His Majesty's Government what assessment they have made of the extent to which patients and their families have been engaged in NICE's project to appraise the effectiveness of vorasidenib.
To ask His Majesty's Government what assessment they have made of the extent to which patients and their families have been engaged in NICE's project to appraise the effectiveness of vorasidenib.
The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS on the basis of an assessment of clinical and cost effectiveness. NICE develops its guidance through extensive engagement with interested parties, including patient groups.
NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over. As part of the appraisal process, NICE’s independent committee was provided with evidence submissions from three patient groups. The committee also heard expert personal perspectives from two patient experts.
The draft guidance was shared with all stakeholders as well as being published on the NICE website for public comment as part of the consultation which took place between 15 October and 4 November 2025. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expects to publish final guidance in January 2026.
To ask His Majesty's Government whether the Patient Safety Incident Response Framework has been fully implemented throughout the NHS to support learning and compassionate responses to families following any incidents.
To ask His Majesty's Government whether the Patient Safety Incident Response Framework has been fully implemented throughout the NHS to support learning and compassionate responses to families following any incidents.
Compliance with the Patient Safety Incident Response Framework (PSIRF) is now a contractual requirement for all services commissioned under the NHS Standard Contract. Implementing the PSIRF is an ongoing process and organisations’ approach to patient safety incident response can and should evolve over time. Work is also underway to explore implementation of the PSIRF in wider services within the National Health Service, such as primary care.
To ask His Majesty's Government what assessment they have made of the impact on the safety and health of patients most at risk of any pressure from NHS England regional teams to focus energies on treating patients with less serious conditions to improve performance against the four-hour waiting time target.
To ask His Majesty's Government what assessment they have made of the impact on the safety and health of patients most at risk of any pressure from NHS England regional teams to focus energies on treating patients with less serious conditions to improve performance against the four-hour waiting time target.
No such assessment has been made. NHS England wrote to systems and trusts on 25 January 2024 reiterating the need to improve accident and emergency performance for all patients requiring emergency care and emphasised some of the known best practice in emergency department processes to ensure delays to patient care are minimised.
Access to National Health Service care and treatment will always be based on clinical priority.
To ask His Majesty's Government what assessment they have made of the impact on patient safety of the reported failures of the Sciensus medicine manufacturing unit.
To ask His Majesty's Government what assessment they have made of the impact on patient safety of the reported failures of the Sciensus medicine manufacturing unit.
Following a report of manufacturing error for a medicine called Cabazitaxel, inspectors from the Medicines and Healthcare products Regulatory Agency (MHRA) visited the manufacturing facility to determine the cause of the error and assess the number of patients who were impacted. Inspectors identified that four patients had received the products, and the products had been administered several weeks previously. MHRA’s review of the incident confirmed the company had already instigated measures to contact the clinicians who were responsible for the patients’ care.
MHRA has taken regulatory action by means of an immediate partial suspension of the licence to manufacture held by Sciensus. This action was taken in accordance with Regulation 28 of the 2012 Human Medicines regulations and ensures that the error is prevented from being replicated whilst further long-term corrective actions are taken by Sciensus assure ongoing patient safety.
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 9 October (HL10239), what guidance they have issued to the NHS to prevent the removal of language in relation to biological sex and women in view of the potential for unintended adverse health consequences.
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 9 October (HL10239), what guidance they have issued to the NHS to prevent the removal of language in relation to biological sex and women in view of the potential for unintended adverse health consequences.
It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.
To ask His Majesty's Government, with reference to the article Practice under pressure: how can the exodus of GPs be reversed published on 31 August by Dr Imelda McDermott and Dr Sharon Spooner, what plans they have to ensure targets for GPs reflect the real-life needs of patients.
To ask His Majesty's Government, with reference to the article Practice under pressure: how can the exodus of GPs be reversed published on 31 August by Dr Imelda McDermott and Dr Sharon Spooner, what plans they have to ensure targets for GPs reflect the real-life needs of patients.
In response to feedback from the profession, work is being undertaken to review the current incentive schemes in primary care, with the aim of making them more focussed and streamlined to give clinicians the flexibility to provide care that is aligned with patient needs. We will consult the profession, patients, and the broader system on primary care incentives this year to inform future reform.
To ask His Majesty's Government, with reference to the article Practice under pressure: how can the exodus of GPs be reversed published on 31 August by Dr Imelda McDermott and Dr Sharon Spooner, what assessment they have made of the impact of the introduction of non-GP staff in practices on...
To ask His Majesty's Government, with reference to the article Practice under pressure: how can the exodus of GPs be reversed published on 31 August by Dr Imelda McDermott and Dr Sharon Spooner, what assessment they have made of the impact of the introduction of non-GP staff in practices on...
NHS England has committed to a review of the Additional Roles Reimbursement Scheme by the end of 2023. This work will cover the performance of the scheme to date and inform the Government’s approach to any future support for additional clinical roles in general practice.
In addition, the Department has funded, via the National Institute for Health and Care Research, a project to look at the impact of non-general practitioner staff in practices on patient care.
Lords motion to regret. Motion withdrawn.
Lords motion to regret. Motion withdrawn.
To ask His Majesty's Government why the Independent Group Advising on the Release of Data only received draft guidance on NHS England’s protection of patient data on 18 January for comment by 20 January.
To ask His Majesty's Government why the Independent Group Advising on the Release of Data only received draft guidance on NHS England’s protection of patient data on 18 January for comment by 20 January.
The Independent Group Advising on the Release of Data (IGARD) were asked to provide feedback on the latest draft of the guidance on a quick turnaround, as the transfer of NHS Digital’s functions to NHS England was conducted at pace because we are keen to see the benefits of creating a single statutory body responsible for data and digital technology for the National Health Service delivered quickly.
This was not intended to be a hard deadline for receiving comments, or the end of the process, as the guidance has not been finalised. We have been reviewing the feedback from IGARD and other stakeholders. The Department would welcome any further feedback that those who were members of IGARD, and others, wish to provide, as we finalise the guidance and then keep it under review.
My officials have discussed the concerns raised by IGARD with NHS England officials.
To ask His Majesty's Government whether they will publish (1) the assessment of the NHS Accelerated Access Collaborative of technologies from the company Healthy.io, (2) any contracts or agreements between Oxfordshire Clinical Commissioning Group and that company, and (3) an estimate of how many Oxfordshire patients had data about them provided...
To ask His Majesty's Government whether they will publish (1) the assessment of the NHS Accelerated Access Collaborative of technologies from the company Healthy.io, (2) any contracts or agreements between Oxfordshire Clinical Commissioning Group and that company, and (3) an estimate of how many Oxfordshire patients had data about them provided...
The NHS Accelerated Access Collaborative (AAC) made a Phase 4 Artificial Intelligence (AI) Award to Healthy.io under Round 1 of the AI Award programme. As part of the award process, the AAC commissioned an independent service evaluation and a randomised controlled trial, supported by Leicester Clinical Trials Unit. The results of these will be published as part of the Award process by September 2024. All 20 Primary Care Networks in Oxfordshire are taking part in the Healthy.io AI Award programme pilot and 2760 patients have been asked if they would like to take part.
The Department does not hold a copy of the contract between Buckinghamshire Oxfordshire and Berkshire West Integrated Care Board and Healthy.io. Our understanding is that this contract was for a pilot project and has not been continued. During the pilot, 38 general practices in Oxfordshire signed up to Healthy.io and submitted 6473 patients, of which 6053 were eligible.
To ask His Majesty's Government what provisions they have made to enable patients to dissent from the secondary use of their patient data within the Federated Data Platform, including pursuant to rights under (1) the National Data Opt-Out, and (2) the Data Protection Act 2018, incorporating the UK General Data...
To ask His Majesty's Government what provisions they have made to enable patients to dissent from the secondary use of their patient data within the Federated Data Platform, including pursuant to rights under (1) the National Data Opt-Out, and (2) the Data Protection Act 2018, incorporating the UK General Data...
Any patient can opt out from the sharing of their data for secondary use purposes in line with the National Data Opt-Out policy. This can be done at any time through the NHS App, online, by phone, email or post. Implementation of the National Data Opt-Out policy has been mandatory for health and adult social care organisations since 31 July 2022.
The procurement process for the Federated Data Platform has not yet commenced. Once operational, data will be treated in accordance with the provisions set out in the Data Protection Act 2018 and UK General Data Protection Regulation. Opted out data will be separated from non-opted out data prior to the commencement of secondary use.
To ask Her Majesty's Government, further to the report by JDRF Research to Reality, published in April, what discussions they have had with the Medicines and Healthcare products Regulatory Agency (MHRA) around embedding patient reported outcomes in their procedures.
To ask Her Majesty's Government, further to the report by JDRF Research to Reality, published in April, what discussions they have had with the Medicines and Healthcare products Regulatory Agency (MHRA) around embedding patient reported outcomes in their procedures.
The Medicines and Healthcare products Regulatory Agency (MHRA) will develop processes for patient engagement and involvement and has committed to publish information on how this is achieved. The MHRA intends to embed these processes by December 2022.
To ask Her Majesty's Government, further to the report by Juvenile Diabetes Research Foundation (JDRF) Research to Reality, published in April, what discussions they have had with the National Institute for Health and Care Excellence (NICE) about embedding patient reported outcomes in their (1) methods, and (2) processes, for reviewing (a) medicines,...
To ask Her Majesty's Government, further to the report by Juvenile Diabetes Research Foundation (JDRF) Research to Reality, published in April, what discussions they have had with the National Institute for Health and Care Excellence (NICE) about embedding patient reported outcomes in their (1) methods, and (2) processes, for reviewing (a) medicines,...
The Department participated in the National Institute for Health and Care Excellence’s (NICE) recent review of its methods and processes for health technology evaluations. Patient-reported outcome measures are embedded throughout NICE’s process and methods for reviewing medicines and medical devices.
I am grateful to the Minister. This is a serious issue. An independent review into cardiac surgery at St George’s Hospital found evidence of shortcomings and a number of avoidable deaths. This finding has been totally contradicted by the senior coroner for inner west London, who found the methodology used in the review completely flawed and said of a particular case that the coroner was dealing with that the doctor’s approach had been without reproach. Given the review that will now be undertaken, does the Minister accept that, if the coroner is right, the whole method used by the NHS for these reviews will come under question?
I am grateful to the Minister. This is a serious issue. An independent review into cardiac surgery at St George’s Hospital found evidence of shortcomings and a number of avoidable deaths. This finding has been totally contradicted by the senior coroner for inner west London, who found the methodology used in the review completely flawed and said of a particular case that the coroner was dealing with that the doctor’s approach had been without reproach. Given the review that will now be undertaken, does the Minister accept that, if the coroner is right, the whole method used by the NHS for these reviews will come under question?
I understand the premise behind the assertion and the Question but, as I explained to the noble Lord yesterday, a number of issues are ongoing—the coroner’s inquest, an employment tribunal and a number of other reviews—which, sadly, I am not allowed to comment on. However, I can say at the moment that we are committed to improving the standard of patient safety investigations. We have set up the independent patient safety investigation service and HSSIB to look at this, as the noble Lord will know from the Bill, and we have a number of independent investigations guidance for standard operating procedures by NHS England and Improvement for teams to use.
To ask Her Majesty’s Government what assessment they have made of the coroner’s ruling on patient deaths at St George’s Hospital which found that deaths were “unnecessary” and the result of “inadequate” NHS-led investigations; and what steps they will take to prevent such failings in future.
To ask Her Majesty’s Government what assessment they have made of the coroner’s ruling on patient deaths at St George’s Hospital which found that deaths were “unnecessary” and the result of “inadequate” NHS-led investigations; and what steps they will take to prevent such failings in future.
NHS England and Improvement will review the coroner’s prevention of future death reports and respond within the agreed timescales. The coroner’s investigations are ongoing. The Government are committed to improving the standard of investigations into serious patient safety incidents in the NHS to create a culture of learning from mistakes and to improve patient safety.
To ask Her Majesty's Government what plans they have to review the functions of the Parliamentary and Health Service Ombudsman to ensure that it (1) collects, (2) analyses, and (3) publishes, data on complaints involving the death of patients that it has decided not to investigate.
To ask Her Majesty's Government what plans they have to review the functions of the Parliamentary and Health Service Ombudsman to ensure that it (1) collects, (2) analyses, and (3) publishes, data on complaints involving the death of patients that it has decided not to investigate.
The Parliamentary and Health Service Ombudsman is a crown servant that reports directly to Parliament. The Ombudsman is not responsible to the Government for its performance and sets its own standards for practice in how it handles complaints. I understand the Noble Lord is in contact with the Ombudsman who can explain in further detail the organisation's current practice in this area. Further to this the Noble Lord may wish to write to the Public Administration and Constitutional Affairs Committee that acts as the primary accountability body for the Ombudsman.
To ask Her Majesty's Government whether they will publish the 2016 NHS Digital report on the Care.data programme.
To ask Her Majesty's Government whether they will publish the 2016 NHS Digital report on the Care.data programme.
We will publish the report on the Care.Data program in the Autumn.
To ask Her Majesty's Government what assessment they have made of any possible correlation between patients being discharged from hospital with COVID-19 (1) to their own homes, and (2) subsequent COVID-19 transmission to family members or paid carers, during the period March 2020 to March 2021.
To ask Her Majesty's Government what assessment they have made of any possible correlation between patients being discharged from hospital with COVID-19 (1) to their own homes, and (2) subsequent COVID-19 transmission to family members or paid carers, during the period March 2020 to March 2021.
No specific assessment has been made.
To ask Her Majesty's Government how many additional cases of COVID-19 have been reported in those care homes approved by Care Quality Commission as ‘designated settings’ for receiving patients discharged from hospital with COVID-19 in England since the scheme was fully implemented.
To ask Her Majesty's Government how many additional cases of COVID-19 have been reported in those care homes approved by Care Quality Commission as ‘designated settings’ for receiving patients discharged from hospital with COVID-19 in England since the scheme was fully implemented.
The Department does not hold the data requested.